Although allogeneic hematopoietic cell transplantation (HCT) is the only proven curative treatment for myelodysplastic syndromes (MDS), it is only used to treat a minority of MDS patients. The majority of patients are too old or suffer from comorbidities rendering allogeneic HCT too risky. Alternative treatment strategies for patients with higher risk MDS try to alter the natural course of disease by preventing or delaying leukemic transformation. In patients with lower risk MDS, treatment is mainly focused on maintaining or improving the quality of life
The myelodysplastic syndromes (MDS) form a heterogeneous group of clonal disorders with an increasin...
AbstractThe landscape of transplantation in myelodysplastic syndrome (MDS) has evolved rapidly in th...
AbstractAllogeneic hematopoietic cell transplantation (allo HCT) is the only curative therapy for th...
Allogeneic stem cell transplantation is a potentially curative treatment for myelodysplastic syndrom...
Myelodysplastic neoplasms, formerly known as myelodysplastic syndromes (MDS), represent a group of c...
Myelodysplastic neoplasms, formerly known as myelodysplastic syndromes (MDS), represent a group of c...
Myelodysplastic neoplasms, formerly known as myelodysplastic syndromes (MDS), represent a group of c...
The incidence of myeloid malignancies, including myelodysplastic syndromes (MDS) increases with age....
AbstractCytoreductive treatment before allogeneic hematopoietic stem cell transplantation (allo-SCT)...
Patients who develop therapy-related myeloid neoplasm, either myelodysplastic syndrome (t-MDS) or ac...
AbstractReduced-intensity conditioning has extended the use of allogeneic hematopoietic stem cell tr...
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment for select...
Therapeutic strategies in MDS range from watchful waiting to allogeneic stem cell transplantation. M...
Therapeutic strategies in MDS range from watchful waiting to allogeneic stem cell transplantation. M...
The myelodysplastic syndromes (MDS) form a heterogeneous group of clonal disorders with an increasin...
The myelodysplastic syndromes (MDS) form a heterogeneous group of clonal disorders with an increasin...
AbstractThe landscape of transplantation in myelodysplastic syndrome (MDS) has evolved rapidly in th...
AbstractAllogeneic hematopoietic cell transplantation (allo HCT) is the only curative therapy for th...
Allogeneic stem cell transplantation is a potentially curative treatment for myelodysplastic syndrom...
Myelodysplastic neoplasms, formerly known as myelodysplastic syndromes (MDS), represent a group of c...
Myelodysplastic neoplasms, formerly known as myelodysplastic syndromes (MDS), represent a group of c...
Myelodysplastic neoplasms, formerly known as myelodysplastic syndromes (MDS), represent a group of c...
The incidence of myeloid malignancies, including myelodysplastic syndromes (MDS) increases with age....
AbstractCytoreductive treatment before allogeneic hematopoietic stem cell transplantation (allo-SCT)...
Patients who develop therapy-related myeloid neoplasm, either myelodysplastic syndrome (t-MDS) or ac...
AbstractReduced-intensity conditioning has extended the use of allogeneic hematopoietic stem cell tr...
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment for select...
Therapeutic strategies in MDS range from watchful waiting to allogeneic stem cell transplantation. M...
Therapeutic strategies in MDS range from watchful waiting to allogeneic stem cell transplantation. M...
The myelodysplastic syndromes (MDS) form a heterogeneous group of clonal disorders with an increasin...
The myelodysplastic syndromes (MDS) form a heterogeneous group of clonal disorders with an increasin...
AbstractThe landscape of transplantation in myelodysplastic syndrome (MDS) has evolved rapidly in th...
AbstractAllogeneic hematopoietic cell transplantation (allo HCT) is the only curative therapy for th...